List/Grid

Tag Archives: annual-meeting

Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease

Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease

A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195). In 2011, the drug crizotinib earned accelerated approval by the US FDA to target the subset of advanced non-small cell lung cancers caused by rearrangements of the anaplastic lymphoma kinase (ALK) gene, and subsequently was granted regular approval in 2013 Continue reading

One step closer to a breath test for lung cancer

One step closer to a breath test for lung cancer

Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present. Continue reading

Patients with metastatic colon cancer respond to new combination therapy

Patients with metastatic colon cancer respond to new combination therapy

In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan. Continue reading

Patients with metastatic colon cancer respond to new combination therapy

Patients with metastatic colon cancer respond to new combination therapy

In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan. Continue reading

Dangers of chemotherapy regimen for bladder cancer patients uncovered by clinical trial

Dangers of chemotherapy regimen for bladder cancer patients uncovered by clinical trial

Patients with muscle-invasive bladder cancer often benefit from chemotherapy before surgery to remove the tumor, but a test of one regimen by researchers at Fox Chase Cancer Center was halted when too many people experienced serious side effects such as heart attacks and blood clots in the legs and lungs. All of the 31 patients included in the study received a combination of gemcitabine and cisplatin, two drugs normally administered for 12 weeks before surgery to remove the tumors Continue reading

Dangers of chemotherapy regimen for bladder cancer patients uncovered by clinical trial

Dangers of chemotherapy regimen for bladder cancer patients uncovered by clinical trial

Patients with muscle-invasive bladder cancer often benefit from chemotherapy before surgery to remove the tumor, but a test of one regimen by researchers at Fox Chase Cancer Center was halted when too many people experienced serious side effects such as heart attacks and blood clots in the legs and lungs. All of the 31 patients included in the study received a combination of gemcitabine and cisplatin, two drugs normally administered for 12 weeks before surgery to remove the tumors Continue reading

Identification of central nervous system involvement for patients with AIDS-related lymphomas

Identification of central nervous system involvement for patients with AIDS-related lymphomas

Patients with AIDS-related lymphomas (ARL) may face an increased risk of central nervous system involvement (CNSi) compared to other lymphomas. The effect of CNSi on survival outcomes, however, hasn’t been thoroughly examined until now. In a new study led by Fox Chase Cancer Center Hematologist and Oncologist Stefan K Continue reading

Identification of central nervous system involvement for patients with AIDS-related lymphomas

Identification of central nervous system involvement for patients with AIDS-related lymphomas

Patients with AIDS-related lymphomas (ARL) may face an increased risk of central nervous system involvement (CNSi) compared to other lymphomas. The effect of CNSi on survival outcomes, however, hasn’t been thoroughly examined until now. In a new study led by Fox Chase Cancer Center Hematologist and Oncologist Stefan K Continue reading

More patients with ovarian cancer are receiving chemotherapy before surgery

More patients with ovarian cancer are receiving chemotherapy before surgery

The use of chemotherapy before surgery to remove ovarian cancer has increased dramatically in recent decades, particularly among certain patients, according to a new analysis from Fox Chase Cancer Center that will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology. Looking back at medical records from more than 58,000 women, Fox Chase’s Angela Jain, MD, Medical Oncologist and co-investigator Elizabeth Handorf, PhD, member of the Biostatistics and Bioinformatics Facility, found that only 8.94% received chemotherapy before ovarian cancer surgery in 1998; by 2011, that figure had increased to 26.72% Continue reading

How Alzheimer’s blood test could be first step in developing treatments to halt or slow disease

How Alzheimer’s blood test could be first step in developing treatments to halt or slow disease

In March of this year, a team of Georgetown University scientists published research showing that, for the first time ever, a blood test has the potential to predict Alzheimer’s disease before patients start showing symptoms. AACC is pleased to announce that a late-breaking session at the 2014 AACC Annual Meeting & Clinical Lab Expo in Chicago will expand upon this groundbreaking research and discuss why it could be the key to curing this devastating illness. According to the World Health Organization, the number of Alzheimer’s patients worldwide is expected to skyrocket from the 35.6 million individuals who lived with it in 2010 to 115.4 million by 2050. Continue reading